Tags

Type your tag names separated by a space and hit enter

IL-15 immunotherapy is a viable strategy for COVID-19.
Cytokine Growth Factor Rev. 2020 08; 54:24-31.CG

Abstract

Coronavirus disease 2019 (COVID-19) is a pulmonary inflammatory disease induced by a newly recognized coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection was detected for the first time in the city of Wuhan in China and spread all over the world at the beginning of 2020. Several millions of people have been infected with SARS-CoV-2, and almost 382,867 human deaths worldwide have been reported so far. Notably, there has been no specific, clinically approved vaccine or anti-viral treatment strategy for COVID-19. Herein, we review COVID-19, the viral replication, and its effect on promoting pulmonary fibro-inflammation via immune cell-mediated cytokine storms in humans. Several clinical trials are currently ongoing for anti-viral drugs, vaccines, and neutralizing antibodies against COVID-19. Viral clearance is the result of effective innate and adaptive immune responses. The pivotal role of interleukin (IL)-15 in viral clearance involves maintaining the balance of induced inflammatory cytokines and the homeostatic responses of natural killer and CD8+ T cells. This review presents supporting evidence of the impact of IL-15 immunotherapy on COVID-19.

Authors+Show Affiliations

Department of Medicine, Tulane Eosinophilic Disorders Centre (TEDC), Section of Pulmonary Diseases, School of Medicine, Tulane University, New Orleans, LA, 70112, USA.Department of Medicine, Tulane Eosinophilic Disorders Centre (TEDC), Section of Pulmonary Diseases, School of Medicine, Tulane University, New Orleans, LA, 70112, USA.Department of Medicine, Tulane Eosinophilic Disorders Centre (TEDC), Section of Pulmonary Diseases, School of Medicine, Tulane University, New Orleans, LA, 70112, USA.Department of Medicine, Tulane Eosinophilic Disorders Centre (TEDC), Section of Pulmonary Diseases, School of Medicine, Tulane University, New Orleans, LA, 70112, USA. Electronic address: amishra@tulane.edu.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

32536564

Citation

Kandikattu, Hemanth Kumar, et al. "IL-15 Immunotherapy Is a Viable Strategy for COVID-19." Cytokine & Growth Factor Reviews, vol. 54, 2020, pp. 24-31.
Kandikattu HK, Venkateshaiah SU, Kumar S, et al. IL-15 immunotherapy is a viable strategy for COVID-19. Cytokine Growth Factor Rev. 2020;54:24-31.
Kandikattu, H. K., Venkateshaiah, S. U., Kumar, S., & Mishra, A. (2020). IL-15 immunotherapy is a viable strategy for COVID-19. Cytokine & Growth Factor Reviews, 54, 24-31. https://doi.org/10.1016/j.cytogfr.2020.06.008
Kandikattu HK, et al. IL-15 Immunotherapy Is a Viable Strategy for COVID-19. Cytokine Growth Factor Rev. 2020;54:24-31. PubMed PMID: 32536564.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - IL-15 immunotherapy is a viable strategy for COVID-19. AU - Kandikattu,Hemanth Kumar, AU - Venkateshaiah,Sathisha Upparahalli, AU - Kumar,Sandeep, AU - Mishra,Anil, Y1 - 2020/06/06/ PY - 2020/05/09/received PY - 2020/06/04/revised PY - 2020/06/05/accepted PY - 2020/6/17/pubmed PY - 2020/9/29/medline PY - 2020/6/16/entrez KW - COVID-19 KW - Cytokine storm KW - Immune cells KW - Interleukin-15 KW - Pulmonary inflammation KW - SARS-CoV-2 SP - 24 EP - 31 JF - Cytokine & growth factor reviews JO - Cytokine Growth Factor Rev VL - 54 N2 - Coronavirus disease 2019 (COVID-19) is a pulmonary inflammatory disease induced by a newly recognized coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection was detected for the first time in the city of Wuhan in China and spread all over the world at the beginning of 2020. Several millions of people have been infected with SARS-CoV-2, and almost 382,867 human deaths worldwide have been reported so far. Notably, there has been no specific, clinically approved vaccine or anti-viral treatment strategy for COVID-19. Herein, we review COVID-19, the viral replication, and its effect on promoting pulmonary fibro-inflammation via immune cell-mediated cytokine storms in humans. Several clinical trials are currently ongoing for anti-viral drugs, vaccines, and neutralizing antibodies against COVID-19. Viral clearance is the result of effective innate and adaptive immune responses. The pivotal role of interleukin (IL)-15 in viral clearance involves maintaining the balance of induced inflammatory cytokines and the homeostatic responses of natural killer and CD8+ T cells. This review presents supporting evidence of the impact of IL-15 immunotherapy on COVID-19. SN - 1879-0305 UR - https://www.unboundmedicine.com/medline/citation/32536564/IL_15_immunotherapy_is_a_viable_strategy_for_COVID_19_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1359-6101(20)30098-8 DB - PRIME DP - Unbound Medicine ER -